Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06100913 · ClinicalTrials.gov registry record · Phase 2
Immunology of Ebola Vaccine
A Phase 2 study of Ebola Virus Disease, sponsored by Emory University.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT06100913 is a Phase 2 study of Ebola Virus Disease that is active but no longer recruiting, run by Emory University. The registered enrollment target is 30 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06100913, a Phase 2 study of Ebola Virus Disease, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study 30 healthy adult participants will receive a single dose of an Ebola vaccine. Blood samples, fine needle aspirates, core biopsies, and bone marrow aspirates will be collected prior to and following vaccination to assess immune responses in the blood, lymph nodes, and bone marrow over multiple time points.
Conditions Studied
Interventions
- BIOLOGICAL Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)
- OTHER Deuterium Labeled Water
Study Locations (2)
Georgia
- The Hope Clinic of the Emory Vaccine Center - Decatur
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06100913
The ClinicalTrials.gov registry entry for NCT06100913 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ebola Virus Disease appearing as the primary indexed condition, and to 2 interventions - of which Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP) is the first listed.
NCT06100913 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Missouri.
Frequently Asked Questions
What is clinical trial NCT06100913 about?
NCT06100913 is a clinical study titled "Immunology of Ebola Vaccine". In this study 30 healthy adult participants will receive a single dose of an Ebola vaccine. Blood samples, fine needle aspirates, core biopsies, and bone marrow aspirates will be collected prior to and following vaccination to assess immune responses in the blood, lymph nodes, and bone marrow over m...
What is the current status of trial NCT06100913?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-08-06. Estimated completion is 2027-08-31.
What conditions does trial NCT06100913 study?
This clinical trial studies the following conditions: Ebola Virus Disease.
What interventions are being tested in trial NCT06100913?
The interventions under investigation include: Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP) (BIOLOGICAL), Deuterium Labeled Water (OTHER).
Who is sponsoring clinical trial NCT06100913?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06100913 being conducted?
This trial has 2 study locations across Georgia, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ebola Virus Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.